Business leaders and public officials say Indiana can turn its manufacturing base into an even bigger advantage by harnessing the power of the internet of things.
Former Apparatus President Aman Brar has launched Canvas Talent Inc., with a software tool that allows recruiters to manage their text conversations with prospective employees.
The mega-merger is set to create a huge publicly traded agricultural company that would be based in Delaware but have major operations in Indianapolis.
ISTEP scores for thousands of students across the state are set to be thrown out this year, including at two Indianapolis private schools, according to state officials.
The updates to the manufacturer’s corporate offices are aimed at collaboration and efficiency. The overpass construction is meant to smooth traffic flow at a key entry point to the city.
Drugmakers like Eli Lilly and Co. plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.
The Speedway contracts with nine software companies and four tech-services firms that are either based in central Indiana or have a substantial local outpost.
Naomi Pescovitz, a North Central High School graduate, will help to launch a 7 p.m. newscast at KMSP-Fox 9, which she said will “give me my weekends back and I’ll be able to turn off that 1:30 a.m. alarm clock.”
David Broecker was founding CEO of the four-year-old Indiana Biosciences Research Institute, which aims to bridge the gap between research universities and industry in life sciences.
Indiana appears to have reached a new normal when it comes to ISTEP scores: For the third straight year, about half of the students taking the exam passed it.
The Paris flights, announced Wednesday, may lessen the urgency local officials feel to attract a direct flight from Indianapolis to London. Delta Air Lines stands to land $5.5 million in incentives if it can keep the flights filled.
li Lilly and Co.’s experimental breast cancer drug abemaciclib, when combined with standard therapy, slowed the progression of tumors in patients with an advanced form of the disease.
A locally-based subsidiary of Japan-based Toyota Industries Corp. plans to spend $8 million to build a 90,720-square-foot factory east of U.S. 31 near 196th Street.
The Indianapolis-based drugmaker is collaborating with CureVac AG to develop up to five cancer products. The products will be based on a new field of biotechnology sweeping the industry.
